Educational needs for prevention of adverse events due to immunotherapy in patients with lung cancer after neoadjuvant therapy:A single-center observational study
10.13406/j.cnki.cyxb.003813
- VernacularTitle:探索新辅助肺癌患者预防免疫药物治疗不良事件的教育需求:一项单中心观察性研究
- Author:
Yabo ZHAO
1
;
Qiang LU
;
Jianyong SUN
;
Qiongjie SHAO
;
Guizhen LI
Author Information
1. 空军军医大学第二附属医院胸腔外科,西安 710038
- Keywords:
neoadjuvant therapy;
lung cancer;
immune-related adverse events;
patient education
- From:
Journal of Chongqing Medical University
2025;50(11):1515-1519
- CountryChina
- Language:Chinese
-
Abstract:
Objective:Immune checkpoint inhibitors(ICIs)can significantly improve the clinical prognosis of various types of cancer and are increasingly used in surgical combination therapy for lung cancer.However,ICIs can cause serious or fatal immune-related ad-verse events(irAEs),and effective patient assessment and family training are essential for the prevention of irAEs in neoadjuvant im-munotherapy.Therefore,this study aims to determine the educational needs for the prevention of irAEs in patients with lung cancer af-ter neoadjuvant therapy.Methods:A retrospective analysis was performed for the medical records of 178 patients with lung cancer who received neoadjuvant therapy from March 2021 to September 2023,and the frequency and severity of irAEs and unplanned hospitaliza-tion due to irAEs were evaluated.Educational needs were assessed based on initial symptoms,caregivers,telephone counselling,and the interval between the appearance of symptoms and the arrival at the hospital.Results:Among the 178 patients available for assess-ment,86 patients(48.3%)experienced irAEs during the study period.Pneumonia observed in 13 patients was the most common irAE requiring hospitalization,followed by dermatitis in 2 patients and adrenal insufficiency in 2 patients.There was a relatively high inci-dence rate of severe irAEs requiring hospitalization among the patients with lung cancer receiving neoadjuvant therapy.Conclusion:Severe irAEs can be avoided through training of related knowledge for patients and their families,timely assessment and reporting of slight changes in symptoms after neoadjuvant therapy by caregivers,focus on commonly observe severe irAEs,and early detection.
